27 / 43
•
114 patients typical/atypical carcinoid (35%)
•
Retrospective analysis
•
Median follow-up 45.1 months
•
90
Y (45p) –
177
Lu (48p) –
90
Y +
177
Lu (21)
Median 58.8 months
Overall Survival
Progression-Free Survival
•
Median ki67.- 7.5%
•
Resection primary 76%
•
Carcinoid syndrome 32%
•
Progressive disease at baseline 78%
•
Previous CT 36%
•
Previous SSA 84%
Mariniello A et al. EJNMMI 2016